EP1025229A4 - CHEMOKINES WITH N-TERMINAL MODIFICATIONS - Google Patents

CHEMOKINES WITH N-TERMINAL MODIFICATIONS

Info

Publication number
EP1025229A4
EP1025229A4 EP98953836A EP98953836A EP1025229A4 EP 1025229 A4 EP1025229 A4 EP 1025229A4 EP 98953836 A EP98953836 A EP 98953836A EP 98953836 A EP98953836 A EP 98953836A EP 1025229 A4 EP1025229 A4 EP 1025229A4
Authority
EP
European Patent Office
Prior art keywords
chemokines
amino
terminal modifications
terminal
modifications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98953836A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1025229A1 (en
Inventor
Stephen H Herrmann
Zhijian Lu
John M Mccoy
Stephen L Swanberg
Bruce Walker
Otto Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Genetics Institute LLC
Original Assignee
General Hospital Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/004002 external-priority patent/WO1998038212A2/en
Priority claimed from US09/175,713 external-priority patent/US6852508B1/en
Application filed by General Hospital Corp, Genetics Institute LLC filed Critical General Hospital Corp
Publication of EP1025229A1 publication Critical patent/EP1025229A1/en
Publication of EP1025229A4 publication Critical patent/EP1025229A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
EP98953836A 1997-10-22 1998-10-21 CHEMOKINES WITH N-TERMINAL MODIFICATIONS Withdrawn EP1025229A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95582697A 1997-10-22 1997-10-22
US955826 1997-10-22
PCT/US1998/004002 WO1998038212A2 (en) 1997-02-28 1998-02-27 Chimeric polypeptides containing chemokine domains
WOPCT/US98/04002 1998-02-27
US09/175,713 US6852508B1 (en) 1997-02-28 1998-10-20 Chemokine with amino-terminal modifications
US175713 1998-10-20
PCT/US1998/022282 WO1999020759A1 (en) 1997-10-22 1998-10-21 Chemokines with amino-terminal modifications

Publications (2)

Publication Number Publication Date
EP1025229A1 EP1025229A1 (en) 2000-08-09
EP1025229A4 true EP1025229A4 (en) 2003-06-18

Family

ID=56289826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98953836A Withdrawn EP1025229A4 (en) 1997-10-22 1998-10-21 CHEMOKINES WITH N-TERMINAL MODIFICATIONS

Country Status (5)

Country Link
EP (1) EP1025229A4 (ja)
JP (1) JP2003526315A (ja)
AU (1) AU758576C (ja)
MX (1) MXPA00003885A (ja)
WO (1) WO1999020759A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130160A0 (en) * 1996-12-02 2000-06-01 Univ Wake Forest Inactivation of HIV co-receptors as therapy for HIV infection
WO2000046248A1 (en) * 1999-02-03 2000-08-10 Schering Corporation Use of agonists or antagonists of mip-3a in therapy
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
MXPA02005199A (es) * 1999-11-24 2002-11-07 Schering Corp Metodos para inhibir metastasis.
US7091310B2 (en) * 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
CN1441808A (zh) * 2000-07-12 2003-09-10 格莱风治疗公司 趋化因子受体调制剂,制备和用途
WO2002010138A2 (en) * 2000-08-01 2002-02-07 Schering Corporation Uses of mammalian genes and related reagents
AU2001288985A1 (en) * 2000-09-13 2002-03-26 Schering Corporation Uses of mammalian genes and related reagents
AU2002235168A1 (en) * 2000-11-05 2002-05-15 University Of Florida Targeting pluripotent stem cells to tissues
JP2005502723A (ja) * 2001-09-20 2005-01-27 シェーリング　コーポレイション 免疫応答のアジュバントとしてのケモカイン
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2004094465A2 (en) * 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
US20100272679A1 (en) 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing
EP2473196B1 (en) 2009-08-28 2017-05-31 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20210388048A1 (en) 2018-10-22 2021-12-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cleavable activators of cxcr3 and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
WO1997037005A1 (en) * 1996-04-02 1997-10-09 Progenics Pharmaceuticals, Inc. Method for preventing hiv-1 infection of cd4+ cells
WO1998004698A1 (fr) * 1996-07-26 1998-02-05 Institut Pasteur Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
WO1997037005A1 (en) * 1996-04-02 1997-10-09 Progenics Pharmaceuticals, Inc. Method for preventing hiv-1 infection of cd4+ cells
WO1998004698A1 (fr) * 1996-07-26 1998-02-05 Institut Pasteur Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LOCKHART EUAN ET AL: "The cloning, expression and purification of cervine interleukin 2.", CYTOKINE, vol. 8, no. 8, 1996, pages 603 - 612, XP002238542, ISSN: 1043-4666 *
See also references of WO9920759A1 *
SIMMONS G ET AL: "POTENT INHIBITION OF HIV-1 INFECTIVITY IN MACROPHAGES AND LYMPHOCYTES BY A NOVEL CCR5 ANTOGONIST", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 276, 1997, pages 276 - 279, XP000887293, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP1025229A1 (en) 2000-08-09
AU758576B2 (en) 2003-03-27
MXPA00003885A (es) 2004-04-23
WO1999020759A1 (en) 1999-04-29
AU758576C (en) 2004-04-29
JP2003526315A (ja) 2003-09-09
AU1110599A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
GB9721360D0 (en) Rack unit
EP1025229A4 (en) CHEMOKINES WITH N-TERMINAL MODIFICATIONS
AU136016S (en) Dish
GB2325398B (en) Shelving
GB9727518D0 (en) Use
GB9704112D0 (en) The Sandelver
ZA988950B (en) Can end
EP0882183A4 (en) PUMP WORKING BY MEANS OF TORQUE TRANSMISSION
GR3035857T3 (en) Shelf
AU2003204941A1 (en) Chemokines with amino-terminal modifications
GB9700448D0 (en) Easy reach
GB9801179D0 (en) Free standing structure
GB9707892D0 (en) Tubing arrangement
TW355287U (en) Combination rack
AU130379S (en) Shelving unit
AU138161S (en) Rack
GB9713280D0 (en) Rack
GB9720682D0 (en) The tube
HU9600215D0 (en) Unit with cross
FI104227B1 (fi) Hyllyrakenne
GB9717746D0 (en) Retaining unit
HU9700162V0 (en) Shelf construction
TW320328U (en) Rack structure
PL106164U1 (en) Shelf
GB9711414D0 (en) Shelf

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

Owner name: GENETICS INSTITUTE, LLC

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/68 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 16/24 B

Ipc: 7C 07K 14/52 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 12N 15/19 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

17Q First examination report despatched

Effective date: 20041004

17Q First examination report despatched

Effective date: 20041004

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070328